Company
Cleara Biotech
- Biotech
- Location:
- Utrecht, Netherlands
Description
Cleara Biotech develops peptide-based therapies that selectively eliminate p53-impaired cancer cells; products include lead development candidates CL04177 and CL04183 for solid tumors and hematological malignancies.
Cleara Biotech is located in the Netherlands ecosystem.
Related
ONK TherapeuticsONK Therapeutics develops off-the-shelf, optimally engineered natural killer (NK) cell therapies combining CAR and TRAIL variant constructs…
Faron PharmaceuticalsFaron Pharmaceuticals creates cancer treatments that use patients’ immune systems, with bexmarilimab, an anti-Clever-1 antibody and myeloid…
ORCA TherapeuticsORCA Therapeutics develops oncolytic virus immunotherapies for prostate cancer, producing lead candidate ORCA-010 for treatment‑naive…
CiMaasCiMaas develops immunotherapy products that expand and engineer natural killer (NK) cells for adoptive cell therapy and CAR‑NK applications…
NTrans TechnologiesNTrans Technologies develops a non-viral delivery platform for cell and gene therapies, providing modular delivery solutions for…
CytovationCytovation develops CyPep-1, a tumor membrane-targeted immunotherapy, using peptide engineering to activate immune recognition and tumor…
Phlox TherapeuticsPhlox Therapeutics develops precision RNA-based therapies to treat rare genetic cardiomyopathies, creating therapeutic candidates and…
CimCureCimCure develops cancer vaccines using its proprietary iBoost conjugate technology to induce immune responses that target and destroy…
Betaglue® TherapeuticsBetaglue® Therapeutics develops localized radiotherapeutic platforms delivering radiation directly into solid tumors, producing precision…